Bone Health Program | Research and Innovation


The Bone Health Program has been actively involved in exploring the causes and symptoms of pediatric low bone density and researching new and improved treatments. Researchers at Boston Children's Hospital are currently investigating:

  • Obese Subjects with Prader-Willi Syndrome to evaluate total body fat mass and food related behavior:
    A randomized, double-blind placebo-controlled phase 3 trial of ZGN-440 in obese subjects with Prader-Willi Syndrome to evaluate total body fat mass.
  • Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer and History of Bone Fracture:
    This study in childhood cancer survivors with history of post-cancer therapy bone fracture will inform the understanding of skeletal fragility assessment.
  • A Novel Diet-Phenotype Interaction Affecting Body Weight:
    How people with different blood insulin levels after consuming carbohydrate respond to different diets for weight loss is compared.
  • Use of Farnesyltransferase inhibitor (FTI) Lonafarnib for Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies: 
    This protocol measures an experimental drug's effect using many tests in hopes that this drug will have therapeutic effect on progeria. 
  • PHACS (PH200) Adolescent Master Protocol (AMP):
    This protocol will look at problems in metabolism such as insulin resistance and diabetes (trouble with blood sugar) and mitochondrial changes that may lead to heart disease. 
  • Acute Lymphoblastic Leukemia (ALL)
  • Defining the Cause of Obesity in Narcolepsy
  • Clinical Study of Spinal Muscular Atrophy
  • Relation of Left Ventricular Mass to Lean Mass and Fat Mass